4basebio (LON:4BB) Given Outperform Rating at Royal Bank Of Canada

Royal Bank Of Canada reissued their outperform rating on shares of 4basebio (LON:4BB) in a report published on Thursday, MarketBeat.com reports. They currently have a GBX 1,600 target price on the stock.

4basebio Price Performance

4BB stock opened at GBX 750.50 on Thursday. The stock has a 50-day moving average price of GBX 872.51 and a two-hundred day moving average price of GBX 1,010. 4basebio has a 12-month low of GBX 704.50 and a 12-month high of GBX 1,500. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The company has a market cap of £116.21 million, a PE ratio of -798.40 and a beta of 1.09.

4basebio (LON:4BB) last posted its quarterly earnings results on Monday, September 29th. The company reported GBX (50) earnings per share (EPS) for the quarter. As a group, research analysts predict that 4basebio will post -3.43 EPS for the current year.

Insider Buying and Selling at 4basebio

In related news, insider Heikki Lanckriet bought 2,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was bought at an average price of GBX 749 per share, with a total value of £14,980. 12.02% of the stock is owned by insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.